Abstract:In the past century, noncommunicable diseases have surpassed infectious diseases as the principal cause of sickness and death, worldwide. Trillions of commensal microbes live in and on our body, and constitute the human microbiome. The vast majority of these microorganisms are maternally derived and live in the gut, where they perform functions essential to our health and survival, including: digesting food, activating certain drugs, producing short-chain fatty acids (which help to modulate gene expression by inhibiting the deacetylation of histone proteins), generating anti-inflammatory substances, and playing a fundamental role in the induction, training, and function of our immune system. Among the many roles the microbiome ultimately plays, it mitigates against untoward effects from our exposure to the environment by forming a biotic shield between us and the outside world. The importance of physical activity coupled with a balanced and healthy diet in the maintenance of our well-being has been recognized since antiquity. However, it is only recently that characterization of the host-microbiome intermetabolic and crosstalk pathways has come to the forefront in studying therapeutic design. As reviewed in this report, synthetic biology shows potential in developing microorganisms for correcting pathogenic dysbiosis (gut microbiota-host maladaptation), although this has yet to be proven. However, the development and use of small molecule drugs have a long and successful history in the clinic, with small molecule histone deacetylase inhibitors representing one relevant example already approved to treat cancer and other disorders. Moreover, preclinical research suggests that epigenetic treatment of neurological conditions holds significant promise. With the mouth being an extension of the digestive tract, it presents a readily accessible diagnostic site for the early detection of potential unhealthy pathogens resident in the gut. Taken together, the data outlined herein provide an encouraging roadmap toward important new medicines and companion diagnostic platforms in a wide range of therapeutic indications.

Microbiome: The missing link between genetics and environmental factors in the case of neurodegenerative diseases?

Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis

Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome

The Relationship Between the Gut Microbiome and Neurodegenerative Diseases

Microbiota and Neurological Disorders: A Gut Feeling

The Microbiota–Gut–Brain Axis and Neurological Disorders: A Comprehensive Review

Gut microbiota: the indispensable player in neurodegenerative diseases

The gut microbiome in neurological disorders

Gut-brain axis: A matter of health and disease in neuropsychiatric disorders…!

The interplay between the gut-brain axis and the microbiome: A perspective on psychiatric and neurodegenerative disorders

Reverse engineering the Gut-Brain Axis and microbiome-metabolomics for symbiotic/pathogenic balance in neurodegenerative diseases

Gut Microbes Associated with Neurodegenerative Disorders: A Comprehensive Review of the Literature

Gut Microbiota Regulation and Their Implication in the Development of Neurodegenerative Disease

Impact of Microbiome-Brain Communication on Neuroinflammation and Neurodegeneration

Oh my gut! Is the microbial origin of neurodegenerative diseases real?

Gut Microbiota Interaction with the Central Nervous System throughout Life

Mechanisms by which microbiome-derived metabolites exert their impacts on neurodegeneration

The Role of the Microbiota–Gut–Brain Axis and Antibiotics in ALS and Neurodegenerative Diseases

The relationship between epigenetics and microbiota in neuropsychiatric diseases

From Microbes to Memories: Challenges and Future Perspectives Regarding the Gut-Brain Axis for Improved Cognitive Health in Alzheimer's

Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside